NCT06703190View on ClinicalTrials.gov

Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated

Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2

BIOLOGICAL

Not vaccinated with 2024-2025 formulated COVID-19 vaccine

The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

CVS Caremark
All Listed Sponsors
collaborator

CVS Caremark

INDUSTRY

lead

Pfizer

INDUSTRY